Trial reportDrug and alcohol dependence2017
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.
Trial report in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Extended-release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review.Addiction (Abingdon, England) · 2025Pooled it
- Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review.Substance abuse treatment, prevention, and policy · 2020Pooled it
- Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.Substance abuse · 2021Trial
- Integrated stepped alcohol treatment for patients with HIV and liver disease: A randomized trial.Journal of substance abuse treatment · 2019Trial
- Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.AIDS and behavior · 2019Trial
- Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Framework for opioid use disorder screening and diagnosis in carceral settings.The International journal on drug policy · 2024Article
- HIV and Substance Use Disorders.Infectious disease clinics of North America · 2024Review
- Prevalence and Correlates of Heavy Alcohol use among People Living with HIV who use Unregulated Drugs in Vancouver, Canada.AIDS and behavior · 2024Article
- Integrated Care Models: HIV and Substance Use.Current HIV/AIDS reports · 2023Review
- Role of the Intersections of Gender, Race and Sexual Orientation in the Association between Substance Use Behaviors and Sexually Transmitted Infections in a National Sample of Adults with Recent Criminal Legal Involvement.International journal of environmental research and public health · 2022Article
- Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation.Journal of acquired immune deficiency syndromes (1999) · 2021Article
- Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders.Patient preference and adherence · 2021Article
- Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.AIDS (London, England) · 2020Article
- Mobile-Enhanced Prevention Support Study for Men Who Have Sex With Men and Transgender Women Leaving Jail: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2020Article
- Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review.Current HIV/AIDS reports · 2020Review
- Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.Journal of substance abuse treatment · 2020Article
- Prevention, screening, and treatment for heavy drinking and alcohol use disorder.The lancet. Psychiatry · 2019Review
- Reduced Sexual Risk Behaviors Among Persons With HIV After Release From the Criminal Justice System.Open forum infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundAlcohol use disorders (AUDs) are highly prevalent among persons living with HIV (PLH) within the criminal justice system (CJS). Extended-release naltrexone (XR-NTX) has not been previously evaluated among CJS-involved PLH with AUDs.
methodsA randomized, double-blind, placebo-controlled trial was conducted among 100 HIV+ prisoners with AUDs. Participants were randomized 2:1 to receive 6 monthly injections of XR-NTX or placebo starting one week prior to release. Using multiple imputation strategies for data missing completely at random, data were analyzed for the 6-month post-incarceration period. Main outcomes included: time to first heavy drinking day; number of standardized drinks/drinking day; percent of heavy drinking days; pre- to post-incarceration change in average drinks/day; total number of drinking days; and a composite alcohol improvement score comprised of all 5 parameters.
resultsThere was no statistically significant difference overall between treatment arms for time-to-heavy-drinking day. However, participants aged 20-29 years who received XR-NTX had a longer time to first heavy drinking day compared to the placebo group (24.1 vs. 9.5days; p<0.001). There were no statistically significant differences between groups for other individual drinking outcomes. A sub-analysis, however, found participants who received ≥4 XR-NTX were more likely (p<0.005) to have improved composite alcohol scores than the placebo group. Post-hoc power analysis revealed that despite the study being powered for HIV outcomes, sufficient power (0.94) was available to distinguish the observed differences.
conclusionsAmong CJS-involved PLH with AUDs transitioning to the community, XR-NTX lengthens the time to heavy drinking day for younger persons; reduces alcohol consumption when using a composite alcohol consumption score; and is not associated with any serious adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.